141 related articles for article (PubMed ID: 9133074)
1. [Current issues in immunotherapy of tumors in the context of macrophage reaction to tissue damage fixed through evolution].
Okulov VB
Vopr Onkol; 1997; 43(1):102-6. PubMed ID: 9133074
[No Abstract] [Full Text] [Related]
2. Liposome-encapsulated macrophage activation agents and active non-specific immunotherapy of neoplastic disease.
Poste G; Kirsh R
Prog Clin Biol Res; 1982; 102 pt A():309-19. PubMed ID: 7167443
[No Abstract] [Full Text] [Related]
3. Utilization of macrophages in anticancer therapy: the macrophage network theory.
Kohchi C; Inagawa H; Hino M; Oda M; Nakata K; Yoshida A; Hori H; Terada H; Makino K; Takiguchi K; Soma G
Anticancer Res; 2004; 24(5C):3311-20. PubMed ID: 15515426
[TBL] [Abstract][Full Text] [Related]
4. [Tumor growth stimulating and inhibiting factors in carcinogenesis].
Kochergina NI; Kosova IP
Usp Sovrem Biol; 1981; 91(3):409-18. PubMed ID: 6457455
[No Abstract] [Full Text] [Related]
5. [Cell therapy in solid tumors].
Ravaud A
Bull Cancer; 2001 Jan; 88(1):91-100. PubMed ID: 11182658
[No Abstract] [Full Text] [Related]
6. [Current trends in the biological therapy of malignant tumors].
Khanson KP; Afanas'ev BV; Bershteĭn LM; Blinov NN; Gershanovich ML; Imianitov EN; Moiseenko VM; Okulov VB; Togo AV
Vopr Onkol; 1996; 42(5):7-12. PubMed ID: 9064908
[No Abstract] [Full Text] [Related]
7. [Thymus hormones in the immunotherapy of malignant neoplasms (a review of the literature)].
Nikol'skiĭ IS
Vrach Delo; 1988 Aug; (8):77-82. PubMed ID: 3061171
[No Abstract] [Full Text] [Related]
8. Molecular approaches to cancer immunotherapy.
Forni G; Cavallo F; Consalvo M; Allione A; Dellabona P; Casorati G; Giovarelli M
Cytokines Mol Ther; 1995 Dec; 1(4):225-48. PubMed ID: 9384678
[TBL] [Abstract][Full Text] [Related]
9. A Breakthrough: Macrophage-Directed Cancer Immunotherapy.
Mills CD; Lenz LL; Harris RA
Cancer Res; 2016 Feb; 76(3):513-6. PubMed ID: 26772756
[TBL] [Abstract][Full Text] [Related]
10. Use of activated natural killer cells for tumor immunotherapy in mouse and human.
Basse PH; Whiteside TL; Herberman RB
Methods Mol Biol; 2000; 121():81-94. PubMed ID: 10818719
[No Abstract] [Full Text] [Related]
11. Perspectives for antitumor therapy based on the recognition mechanism by which macrophages identify undesirable foreign and native cells and molecules.
Takiguchi K; Inagawa H; Nishizawa T; Kohchi C; Soma G
Anticancer Res; 2002; 22(6C):4277-80. PubMed ID: 12553069
[TBL] [Abstract][Full Text] [Related]
12. Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors.
Lotfi R; Lee JJ; Lotze MT
J Immunother; 2007 Jan; 30(1):16-28. PubMed ID: 17198080
[TBL] [Abstract][Full Text] [Related]
13. [Mechanisms of the antineoplastic action of viruses and the problem of the immunotherapy of tumors].
Ferdat AK; Mutsenietse AIa
Vopr Onkol; 1988; 34(11):1291-300. PubMed ID: 2849245
[No Abstract] [Full Text] [Related]
14. Recognition factors and nonspecific macrophage activation in the treatment of neoplastic disease.
Mansell PW; DiLuzio NR; McNamee R; Rowden G; Proctor JW
Ann N Y Acad Sci; 1976; 277(00):20-44. PubMed ID: 63258
[No Abstract] [Full Text] [Related]
15. Complement function in mAb-mediated cancer immunotherapy.
Gelderman KA; Tomlinson S; Ross GD; Gorter A
Trends Immunol; 2004 Mar; 25(3):158-64. PubMed ID: 15036044
[No Abstract] [Full Text] [Related]
16. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
17. Combined chemo- and immunotherapy of tumors induced in mice by bcr-abl-transformed cells.
Sobotkova E; Duskova M; Tachezy R; Petrackova M; Vonka V
Oncol Rep; 2009 Mar; 21(3):793-9. PubMed ID: 19212641
[TBL] [Abstract][Full Text] [Related]
18. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy.
Wojtowicz-Praga S
J Immunother; 1997 May; 20(3):165-77. PubMed ID: 9181454
[TBL] [Abstract][Full Text] [Related]
19. The ongoing evolution of dendritic cell therapy.
Sokoloff MH; Vogelzang N
Cancer; 1999 Dec; 86(12):2593-6. PubMed ID: 10594853
[No Abstract] [Full Text] [Related]
20. Dendritic cell-based cancer therapy.
Conrad C; Nestle FO
Curr Opin Mol Ther; 2003 Aug; 5(4):405-12. PubMed ID: 14513684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
